Foundation welcomes new members to advance its mission
Site Search
On Thursday, January 14 at 7 p.m. ET the CF Foundation will host a live town hall where top questions about the COVID-19 vaccines will be answered by a panel of experts. Register here.
The Cystic Fibrosis Foundation recently submitted comments to the National Institutes of Health on improving racial equity, diversity, and inclusion in the biomedical research workforce.
FDA issues emergency use authorization for a third COVID-19 vaccine.
The Cystic Fibrosis Foundation has renewed its commitment to supporting the health and well-being of adults living with cystic fibrosis by supporting free access to the online exercise, education, and well-being platform, Beam.
Vertex Pharmaceuticals Inc. has submitted three supplemental New Drug Applications to the U.S. Food and Drug Administration (FDA) to expand eligibility for Trikafta® (elexacaftor/tezacaftor/ivacaftor), Symdeko® (tezacaftor/ivacaftor and ivacaftor) and Kalydeco® (ivacaftor) to additional rare CFTR mutations.
Today, Vertex Pharmaceuticals Inc. announced positive Phase 3 clinical trial data for Trikafta® (elexacaftor/tezacaftor/ivacaftor) in children 6-11 years old with cystic fibrosis.
Roche has acquired a set of potentiator compounds from Enterprise Therapeutics and intends to study them for the treatment of CF. The Cystic Fibrosis Foundation previously provided funding to Enterprise to develop these potential medicines.
Legislation Would Remove Financial Penalties for Participating in Research Studies